Molecular Classification Improves Therapeutic Options for Infants and Young Children With Medulloblastoma.

ABSTRACT: Medulloblastoma in infants and young children is a major challenge to treat because craniospinal irradiation (CSI), a cornerstone of therapy for older children, is disproportionately damaging to very young children. As a result, trials have attempted to delay, omit, and replace this therapy. Although success has been limited, the approach has not been a complete failure. In fact, this approach has cured a significant number of children with medulloblastoma. However, many children have endured intensive regimens of chemotherapy only to experience relapse and undergo salvage treatment with CSI, often at higher doses and with worse morbidity than they would have initially experienced. Recent advancements in molecular diagnostics have proven that response to therapy is biologically driven. Med

SUBMITTER: Bagchi A 

PROVIDER: S-EPMC10765405 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature